Is This Biotech Upgrade Deserved?

In the following video, health care editor/analyst David Williamson discusses the recent analyst upgrade that sent shares of Keryx Pharmaceuticals soaring 30% over the last couple of trading sessions. After handing back perifosine to its partner Aeterna Zentaris, Keryx is regaining momentum after a successful phase 3 trial of its other drug candidate, Zerenex. To find out whether this newfound bullish sentiment is deserved, watch the video and Fool On.

Keryx may be too risky to become one of the many dynamic recommendations made to Motley Fool Rule Breakers subscribers, but now's a great time to discover the next rule-breaking multibagger that the newsletter has unearthed. It's a free report. Want it? Get it.

At the time thisarticle was published David Williamsonowns shares of Pfizer, but he holds no other position in any company mentioned.Click hereto see his holdings and a short bio.Motley Fool newsletter serviceshave recommended buying shares of Pfizer. The Motley Fool has adisclosure policy. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.